Cell Therapeutics Announces Results from Preclinical Study of Pixantrone at AACR-NCI-EORTC Conference

Cell Therapeutics (NASDAQ: CTIC ) today announced the presentation of findings from a preclinical study of PIXUVRI that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin. PIXUVRI is a first-in-class aza-anthracenedione with unique structural and physiochemical properties that